Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics
Background: Severe mental illnesses are associated with increased risks for metabolic syndrome (MetS) and other medical disorders, often with unfavorable outcomes. MetS may be more likely with schizoaffective disorder (SzAff) than schizophrenia (Sz). MetS is associated with long-term antipsychotic d...
Main Authors: | Antonio Ventriglio, Ross J. Baldessarini, Giovanna Vitrani, Iris Bonfitto, Angela Chiara Cecere, Angelo Rinaldi, Annamaria Petito, Antonello Bellomo |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-01-01
|
Series: | Frontiers in Psychiatry |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fpsyt.2018.00744/full |
Similar Items
-
Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland
by: Stephan Reymann, et al.
Published: (2022-03-01) -
Schizophrenia long-acting antipsychotics initiation index (SLAAII)
by: P. Ifteni, et al.
Published: (2021-04-01) -
Evaluation of long acting, oral and combination antipsychotic treatments in patients with psychotic disorder (tur)
by: Yasir Şafak, et al.
Published: (2020-01-01) -
Long-acting injectable antipsychotics during pregnancy: An update
by: A. Paraschakis, et al.
Published: (2021-04-01) -
The combination of long-acting injectable antipsychotics, a new key in resistant schizophrenia
by: M.F. Tascón Guerra, et al.
Published: (2022-06-01)